Overview

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Status:
RECRUITING
Trial end date:
2029-05-01
Target enrollment:
Participant gender:
Summary
A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers
Phase:
PHASE1
Details
Lead Sponsor:
Bolt Biotherapeutics, Inc.